An interventional study of Analysis of social functioning and social cognition processes in Alcohol Use Disorder, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by CHU de Reims · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Alcoholism with a site in France — 24 open to participants now, 25 under way, 1 of them phase 3. Alcoholism · France.
Among the 94 studies in Alcoholism with a site in France, this one is the 48th largest by planned enrollment of the 58 interventional ones that give a count, is one of 8 that started in 2026, is one of 42 with no phase, reaches primary completion later than 21 of the 24 other live ones, and was the 90th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →24 of the 94 studies in Alcoholism with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18–65
Hospices Civils de Lyon · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+ · Healthy volunteers
CHU de Reims · Sites in France
Ages 24+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 8 · Phase 4 2
First in 2002; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 153 across the 58 interventional studies, 113 across the 36 observational. Of the 59 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 94 have an industry lead sponsor. The 10 most frequent:
CHU de Reims is the lead sponsor of 276 studies on the registry; 50 are open to participants now.
CHU de Reims has 4 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
5 of the studies in Alcoholism with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369245Versailles HospitalTechniques for Activating Consciousness (TAC) for Outpatients With Moderate to Severe Alcohol Addiction | 2027-07-15 |
| NCT04773691Centre Hospitalier Universitaire DijonEffectiveness of High-frequency rTMS in Reducing Alcohol Consumption in Non-abstinent Patients With an Alcohol Use Disorder | 2027-08 |
| NCT06706349Centre Hospitalier Universitaire de BesanconEffect of Adapted Physical Activity on Sleep Quality in People With Alcohol Use Disorder | 2027-10 |
| NCT06675539Etablissement Public de Santé Barthélemy DurandValidation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS) | 2027-10 |
| NCT07844720Institut National de la Santé Et de la Recherche Médicale, FranceStudy on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With Alcohol Use Disorder | 2027-10-22 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Alcoholism with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
With 41,000 deaths per year, alcohol consumption is the second leading cause of preventable mortality in France. Nearly 3.4% of adults engage in excessive and chronic alcohol use, meeting criteria for Severe Alcohol Use Disorder (SAUD).
SAUD is associated with cerebral and cognitive alterations, including deficits in social cognition. These deficits manifest as difficulties in perceiving and interpreting social cues during interactions and encompass, in particular, the recognition of emotional facial expressions and the accurate attribution of others' beliefs, emotions, and intentions (i.e., theory of mind). Such alterations contribute to interpersonal difficulties and psychological distress and are recognized as risk factors for the development and maintenance of SAUD.
To date, social cognition has primarily been explored through behavioral tests, providing a description of deficits without examining their neuro-structural correlates. Moreover, no neuroscientific study has investigated the impact of sex and concomitant tobacco use on social cognition and associated brain structures in SAUD, although these factors are known to influence both social cognitive abilities and cerebral organization in this disorder. Finally, the everyday consequences of these alterations on social functioning and the trajectory of alcohol consumption remain poorly explored.
In this context, the present project aims, first, to explore the neuro-structural correlates of social cognition deficits in SAUD using psychometric assessments (i.e., emotion recognition, theory of mind) combined with magnetic resonance imaging (MRI). The impact of sex and tobacco use will be accounted for by including these variables as covariates in statistical analyses. Second, the project seeks to assess the daily-life impact of social cognition deficits on the social functioning of individuals with SAUD (i.e., quantity and quality of social interactions) and on the evolution of alcohol use behaviors six months after hospitalization (i.e., risk of relapse).
The study will include two participant groups: individuals with SAUD and age-, sex-, and education-matched control participants.
The expected results will refine our understanding of social cognition alterations in SAUD, thereby contributing to the improvement of current neuroscientific models. These advances will pave the way for the identification of potential targets for prevention programs and therapeutic interventions.
Nearly 3.4% of adults engage in excessive and chronic alcohol use, meeting criteria for Severe Alcohol Use Disorder (SAUD). SAUD is associated with cerebral and cognitive alterations, including deficits in social cognition. These deficits manifest as difficulties in perceiving and interpreting social cues during interactions and encompass, in particular, the recognition of emotional facial expressions and the accurate attribution of others' beliefs, emotions, and intentions (i.e., theory of mind). Such alterations contribute to interpersonal difficulties and psychological distress and are recognized as risk factors for the development and maintenance of SAUD.
To date, social cognition has primarily been explored through behavioral tests, providing a description of deficits without examining their neuro-structural correlates. Moreover, no neuroscientific study has investigated the impact of sex and concomitant tobacco use on social cognition and associated brain structures in SAUD, although these factors are known to influence both social cognitive abilities and brain organization in this disorder. Finally, the everyday consequences of these alterations on social functioning and the trajectory of alcohol consumption remain poorly explored.
In this context, the present project aims, first, to explore the neuro-structural correlates of social cognition deficits in SAUD using psychometric assessments (i.e., emotion recognition, theory of mind) combined with magnetic resonance imaging (MRI). The impact of sex and tobacco use will be accounted for by including these variables as covariates in statistical analyses. Second, the project seeks to assess the daily-life impact of social cognition deficits on the social functioning of individuals with SAUD (i.e., quantity and quality of social interactions) and on the evolution of alcohol use behaviors six months after hospitalization (i.e., risk of relapse).
The study will include two participant groups: individuals with SAUD and age-, sex-, and education-matched control participants. The expected results will refine our understanding of social cognition alterations in SAUD, thereby contributing to the improvement of current neuroscientific models. These advances will pave the way for the identification of potential targets for prevention programs and therapeutic interventions.
Detailed Description
State of the Art Severe Alcohol Use Disorder (SAUD) is associated with structural and functional brain alterations as well as cognitive impairments affecting memory and executive functions. Recent research also highlights deficits in social cognition, including emotion recognition and theory of mind.
However, the neural correlates of these deficits remain poorly understood. Most neuroimaging studies in SAUD have focused on functional MRI tasks involving implicit emotional processing, whereas clinical neuropsychology typically relies on explicit behavioral assessments. Consequently, the structural brain correlates (gray and white matter) of social cognition deficits in SAUD remain largely unexplored.
Social cognition impairments may contribute to difficulties in daily social functioning and could increase relapse risk. Ecological Momentary Assessment (EMA), combined with passive smartphone data, enables real-time assessment of social interactions in naturalistic settings and may provide a more accurate measure of daily social functioning than retrospective reports.
Aims of this protocol
Primary Objective:
- To investigate structural brain correlates (gray matter and white matter) of social cognition deficits (emotion recognition and theory of mind) in patients with SAUD.
Secondary Objectives:
Hypotheses Social Cognition and Brain Alterations H1a: SAUD patients will show reduced gray matter volume and white matter integrity in brain regions involved in socio-emotional processing.
H1b: Structural alterations will be associated with performance on social cognition tasks.
H1c: Sex and tobacco use may modulate these associations. Social Cognition and Daily Functioning H2: Cognitive and brain deficits will predict poorer daily social functioning, assessed through self-reported interactions and passive smartphone data.
Social Cognition and Relapse H3: Cognitive and brain deficits will predict relapse risk (alcohol consumption, craving, anxiety, depression) six months after detoxification.
Recruitment of participants
Two groups will be recruited:
SAUD patients (n = 30): Individuals hospitalized for alcohol withdrawal, abstinent for at least two weeks, without other substance use disorders (except tobacco use disorder and occasional cannabis consumption) or severe psychiatric/neurological illness.
Healthy controls (n = 30): Individuals without substance use disorders or severe psychiatric/neurological illness, matched for age and socioeconomic status.
Levels of investigation Clinical Assessment: A physician specialized in addiction medicine will collect sociodemographic and clinical data, including alcohol and drug use, psychiatric symptoms, impulsivity, and socio-emotional functioning (e.g., empathy, alexithymia, emotion regulation).
Neuropsychological Assessment: Participants will complete tests assessing general cognitive functioning, executive functions (inhibition, mental flexibility), and social cognition (facial emotion recognition and theory of mind).
MRI: MRI acquisition will include structural T1-weighted imaging, diffusion tensor imaging (DTI), and functional MRI during the viewing of two short movie clips.
Ecological Momentary Assessment (EMA): For 14 days following the MRI session, participants will complete a daily smartphone questionnaire assessing social interactions. Passive smartphone data (e.g., call frequency, time on communication apps, step count) will also be collected to estimate social activity.
Assessments will occur at multiple time points:
Structural MRI analyses will assess gray matter volume, cortical thickness, and cortical surface area across the whole brain and within social cognition-related regions of interest. White matter integrity will be evaluated using diffusion measures (fractional anisotropy, mean diffusivity) and tractography.
Regression analyses will identify predictors of social cognition deficits, daily social functioning (EMA and passive data), and relapse outcomes.
AUD patients
Inclusion criteria:
Exclusion criteria:
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alcohol Use Disorder patients
Behavioral: Analysis of social functioning and social cognition processes
Healthy control participants matched to group 1
Behavioral: Analysis of social functioning and social cognition processes
Investigation of functioning and social cognition processes using a comprehensive, neuropsychological assessment and MRI exam. * Evaluation of addictive, psychiatric and neurological comorbidities. * Neuropsychological assessment establishing the participants cognitive profiles of executive functions and of social cognition * Collection of smartphone-based data that is descriptive of participants daily social functioning * MRI exam identifying participants neuroanatomical and neurofunctional correlates of social cognition processes
MRI exam: brain structures
Evaluated through a high-resolution 3D anatomical image, diffusion tensor images and a functional MRI sequence (passive visualization of two short movie clips). Examination of brain structures to identify the neuroanatomical and neurofunctional correlates of social cognition processes in the Alcohol Use Disorder patients.
Time frame: Day 3
Social cognition: facial emotion recognition
Evaluated through a test of facial emotion recognition (TREF). The participant is shown 54 photographs depicting 6 different emotions of variable intensity (joy, anger, sadness, disgust, contempt, fear) for which he must choose the corresponding emotion label. Are measured participant's response times, the number of correct responses (score out of 54) and type of errors. (Gaudelus, B., Virgile, J., Peyroux, E., b, Leleu, A., c, Baudouin J.Y., Franck N. (2015). Mesure du déficit de reconnaissance des émotions faciales dans la schizophrénie. Étude préliminaire du test de reconnaissance des émotions faciales (TREF). L'Encéphale 41(3), 251-259.)
Time frame: Day 2
Social cognition: cognitive and affective theory of mind
Evaluated through The Movie of Assessment for Social Cognition (MASC). The participant is shown a movie of approximately 15 minutes displaying people interacting with each other. From time to time, the movie is stopped, and the participant must answer different questions relating to the thoughts and feelings of the characters. Are measured the number of correct responses out of 45. (Dziobek I, Fleck S, Kalbe E, Rogers K, Hassenstab J, Brand M, Kessler J, Woike JK, Wolf OT, Convit A.J (2006). Journal of Autism and Developmental Disorders 36(5), 623-36.)
Time frame: Day 2
Everyday social functioning: EMA and passive smartphone data
Daily social functioning will be assessed using Ecological Momentary Assessment (EMA) via the Behapp application (University of Groningen). Behapp will send a daily questionnaire to the participant's smartphone at the end of the day for 14 consecutive days, assessing the quantity and quality of social interactions through 20 items. The Behapp app collects passive mobile data providing a more comprehensive evaluation of social functioning : Number and duration of incoming and outgoing phone calls (only metadata are collected), time spent on social media applications (only aggregated data are collected), number of unique locations visited (without GPS coordinates or exact addresses), screen states and movement patterns (e.g., step counts). (Jagesar, R. R., at al (2021). Digital phenotyping and the COVID-19 pandemic: capturing behavioral change in patients with psychiatric disorders. European Neuropsychopharmacology, 42, 115-120.)
Time frame: During 14 days
Executive functions: mental flexibility performances and processing speed
Evaluated through the Trail Making Test (TMT parts A and B). In part A the participant must connect as quick as possible all the numbers on a sheet of paper in ascending order (1-25). In part B the participant is asked to connect all the numbers in ascending order (1-13) and all the letters according to their alphabetical order (A-L) whilst alternating between numbers and letters and without lifting the pencil. For both parts is reported the time necessary for task completion in seconds. (Reitan RM, Wolfson D (1985) The Halstead-Reitan Neuropsychological Test Battery. Neuropsychology Press, Tucson, AZ.)
Time frame: Day 2
Started May 2026 (actual). Primary completion is estimated for Nov 2028, 30 months after the start.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 30 months is below that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.